Ozalin (Midazolam)

Midazolam, the active ingredient in Ozalin, is a benzodiazepine presented as a 1 mg/ml solution for intravenous use. It is employed to induce sedation, anxiolysis, and amnesia in procedural settings, primarily for adult patients.

GNH USA supplies Ozalin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Midazolam acts on the central nervous system to provide rapid sedation and anxiolysis in several clinical scenarios. - Procedural sedation: facilitates calmness and amnesia during minor surgical or diagnostic procedures. - Pre‑operative anxiety: reduces anxiety before induction of general anesthesia. - Seizure emergencies: helps terminate short‑lasting seizures such as those seen in status epilepticus – provides rapid anticonvulsant effect. - Intensive‑care sedation: maintains a controlled level of sedation for mechanically‑ventilated patients.

Midazolam may cause a range of adverse reactions, from mild to potentially life‑threatening.

Common Side Effects: - Drowsiness - Dizziness - Amnesia - Headache - Nausea - Mild respiratory depression

Serious or Rare Side Effects: - Severe respiratory depression - Hypotension - Paradoxical agitation or aggression - Cardiac arrhythmias - Anaphylactic reaction - Persistent sedation lasting beyond the procedure

Midazolam should be used only with careful clinical monitoring and appropriate patient selection. - Respiratory monitoring: continuous observation of breathing rate and oxygen saturation is essential. - Cardiovascular assessment: watch for hypotension or arrhythmies especially in patients with cardiac disease. - Concomitant CNS depressants: avoid or dose‑reduce when combined with opio‑ like opioids and alcohol. - Pregnancy and lactation: use only if clearly beneficial and benefits risk ‑ the drug should be avoided unless necessary by the clinician. - Elderly patients: start at lower dose and titrate slowly. - Store at ambient temperature: keep in the original vial or container and protect from moisture and light to ensure stability.

Midazolam interacts with several drug classes that can modify its sedative effect.

Major Interactions (Avoid): - Opioids: combined use markedly strong ens ens strong sedation and respiratory depression. - Azole fungal agents (e.g., ketoconazole): inhibit CYP 3A4 and raise midazolam plasma levels. - Macrolide antibiotics (e.g., erythromycin): CYP 3A4 inhibition leading to increased exposure.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): may enhance central nervous system depression. - Anticonvulsants (phenyphine) : potential pharmacokinetic interaction with mid  g  g

g

g

g

g

g

g ",